Company / R&D per Share
Vertex Pharmaceuticals R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$15.22
FY2025
5-year range
$9.98 / $15.22
FY2021-FY2025
Trend
+8.0%
vs FY2024
Sector context
#8 of 208
Health Care
What the data says
Among 208 Health Care companies, Vertex Pharmaceuticals is in the top 4% for r&d per share. R&D per Share has increased for 3 consecutive years, from $9.98 in FY2022 to $15.22 in FY2025.
Based on SEC 10-K filings.
15.22 in FY2025 with a 5-year CAGR of +16.6%. Top quartile in the Health Care sector.
Improved from $12.31 to $15.22 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +15.1%
- 5-Year CAGR
- +16.6%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 208This company $15.22 Sector average $28.82
▼
-47.2% below sector average
Key checks
Key Insights
- Vertex Pharmaceuticals's r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 8.0% year-over-year.
- Ranks #8 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.22 | +8.0% |
| FY2024 | $14.09 | +14.5% |
| FY2023 | $12.31 | +23.3% |
| FY2022 | $9.98 | -15.0% |
| FY2021 | $11.74 | +66.2% |
| FY2020 | $7.06 | +2.7% |
| FY2019 | $6.88 | +22.9% |
| FY2018 | $5.59 | +4.8% |
| FY2017 | $5.33 | +25.4% |
| FY2016 | $4.25 | +3.3% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026